Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?
J Thorac Dis
.
2012 Apr 1;4(2):226-8.
doi: 10.3978/j.issn.2072-1439.2012.03.14.
Authors
Lorenza Landi
1
,
Federico Cappuzzo
Affiliation
1
Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100 Livorno, Italy.
PMID:
22833835
PMCID:
PMC3378224
DOI:
10.3978/j.issn.2072-1439.2012.03.14
No abstract available